WCLC interview with Professor Dong Xiaorong: Radiotherapy has always played a role in the treatment of lung cancer

foreword

The 2022 International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer (WCLC) kicked off from August 6 to 9, 2022 in an offline + online format

Expert Profile

Professor Dong Xiaorong

• Third-level professor chief physician doctoral tutor

• Deputy Director, Department of Oncology/Teaching and Research Section, Union Hospital, Huazhong University of Science and Technology

• Director, Department of Thoracic Oncology, Cancer Center, Union Hospital, Huazhong University of Science and Technology 

• Director of Chinese Society of Clinical Oncology

• Vice-chairman of Lung Cancer Special Committee of China Medical Education Association

• Member of the Standing Committee of the Lung Cancer Expert Committee of the Chinese Anti-Cancer Association

• Member of the Standing Committee of the Immunology Expert Committee of the Chinese Society of Clinical Oncology

• Member of the Standing Committee of the Expert Committee on Vascular Targeted Therapy, Chinese Society of Clinical Oncology

• Member of the Standing Committee of the Patient Education Expert Committee of the Chinese Society of Clinical Oncology

• Member of the non-small cell lung cancer expert committee of the Chinese Society of Clinical Oncology

• Chairman of the Tumor Immunotherapy Special Committee of Hubei Anti-Cancer Association

• Vice-chairman of the Medical Oncology Treatment Committee of Hubei Anti-Cancer Association

Yimaitong: Radiotherapy is an important local treatment for patients with early or locally advanced NSCLC, while systemic therapy is the mainstay for advanced patients

Professor Dong Xiaorong: Surgery, radiotherapy and chemotherapy are the three traditional methods of tumor treatment

Yimaitong: With the rapid progress of immunotherapy, immunotherapy combined with chemotherapy has become one of the first-line standard treatment options for advanced NSCLC, while the research data of immunotherapy combined with radiotherapy are limited

Professor Dong Xiaorong: For advanced NSCLC, especially for patients with negative driver genes, immune checkpoint inhibitor therapy based on PD-1/PD-L1 monoclonal antibody has become one of the standard treatments

Can the addition of radiotherapy bring survival benefits to patients? How safe is the treatment? Based on these doubts, our team conducted a retrospective study

Yimaitong: What is the efficacy of radiotherapy in patients with brain metastases from NSCLC? You have another study (oral presentation) exploring the efficacy of ctDNA in predicting the efficacy of radiation therapy in patients with brain metastases

Professor Dong Xiaorong: The brain is one of the most common metastatic sites in lung cancer patients, and it is actually a local manifestation of the systemic disease of lung cancer

Circulating tumor DNA (ctDNA) is a DNA fragment derived from the necrosis, apoptosis and secretion of tumor cells, widely distributed in various body fluids including peripheral blood and cerebrospinal fluid, and has been applied to NSCLC patients with brain metastases

30NSCLC，、 24(T0)28(T28) ，ctDNA
。
8375
。
，ctDNA55%
。
EGFR、DNMT3A、TP53、LRP1BTET2
。
EGFR、ZFHX3、TP53、KDM6A、LRP1B
。

（MAF），（TMB）
。

，24，T28 ctDNA OSPFS，
。
，，ctDNA
。
ctDNANSCLC
。

：，WCLC？

: 2022WCLC,GEMSTONE-301PFS，IIINSCLC，PD-1，+、
。